抢先看！2025 SABCS公布70余项口头报告，核心看点一文速览

GS1-01：Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer

Her2climb-05试验：tucatinib对比安慰剂联合曲妥珠单抗与帕妥珠单抗用于HER2+转移性乳腺癌维持治疗的随机、双盲 3 期研究

讲者：Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN

GS1-02：Efficacy and safety of neoadjuvant trastuzumab deruxtecan versus standard of care chemotherapy plus trastuzumab plus pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV

WSG-ADAPT-HER2-IV 试验：新辅助德曲妥珠单抗对比标准化疗联合曲妥珠单抗与帕妥珠单抗用于 HER2+ 早期乳腺癌的疗效与安全性

讲者：Nadia Harbeck, LMU University Hospital, Munich, Germany

GS1-03：Discussant for GS1-01 and GS1-02:Evolving landscape of her2+ breast cancer

讲者：Ciara C O'Sullivan, Mayo Clinic, Rochester, MN

GS1-04：Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: an exploratory analysisfrom the ALTTO (BIG 2-06) trial

芳香化酶抑制剂或他莫昔芬辅助治疗HR+/HER2+早期乳腺癌患者的疗效：来自 ALTTO（BIG 2-06）试验的探索性分析

讲者：Matteo Lambertini, University of Genova – IRCCS Ospedale Policlinico San Martino, Genoa, Italy

GS1-05：Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN-1181/CompassHER2 pCR trial

THP方案治疗的Ⅱ/Ⅲ期HER2+ 乳腺癌中的肿瘤浸润淋巴细胞（TILs）与病理完全缓解（pCR）：来自ECOG-ACRIN-1181/CompassHER2 pCR试验的次要结果

讲者：Sunil S Badve, Emory School of Medicine, Atlanta, GA

GS1-06：Prognostic and predictive associations of manual, digital and AI-derived tumor infiltrating lymphocytes-scoring: A retrospective analysis from the Phase III APHINITY trial

人工、数字及人工智能（AI）衍生的肿瘤浸润淋巴细胞评分的预后与预测价值：来自 3 期 APHINITY 试验的回顾性分析

讲者：Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia

GS1-07：Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study

HER2+早期乳腺癌中的循环肿瘤 DNA（ctDNA）：PHERGain 新辅助个体化治疗研究的转化分析

讲者：Antonio Llombart-Cussac, Hospital Arnau de Vilanova; Translational Oncology Group, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU; Medica Scientia Innovation Research (MedSIR), Valencia, Spain

GS1-08：Discussant for GS1-05, GS1-06, GS1-07

讲者：Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

GS1-09：Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx

在TAILORx研究中，整合图像、临床和分子数据的多模态人工智能（AI）模型用于预测乳腺癌的早期和晚期复发

讲者：Joseph A Sparano, Icahn School of Medicine at Mount Sinai, New York, NY

GS1-10：Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07

ASCENT-07研究的主要结果：戈沙妥珠单抗对比化疗作为HR+/HER2-（IHC 0, 1+, 2+/ISH-）转移性乳腺癌内分泌治疗后的首个治疗方案

讲者：Komal L. Jhaveri, Memorial Sloan Kettering Cancer Center (MSKCC); Weill Cornell Medical College, New York, NY

GS2-01：More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy – primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R)study

国际前瞻性多中心 AXSANA/EUBREAST 3 (R) 试验的主要终点分析：新辅助化疗后从临床淋巴结阳性转为临床淋巴结阴性的乳腺癌患者中，更具侵入性与低侵入性腋窝手术分期方案的比较

讲者：Thorsten Kühn, Die Filderklinik gGmbH / University of Ulm, Ulm, Germany

GS2-02：Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial

1-3枚前哨淋巴结宏转移且接受保乳治疗的乳腺癌患者的腋窝手术：INSEMA 试验的次要结果

讲者：Toralf Reimer, University of Rostock, Rostock, Germany

GS2-03：Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial

INSEMA试验的次要结果：接受保乳手术（伴或不伴腋窝前哨淋巴结活检）患者的放射治疗应用见解

讲者：Guido Hildebrandt, University Medicine Rostock, Rostock, Germany

GS2-04：Heating up cold tumors: single-cell mapping of immune and adenosine pathway reprogramming in luminal B breast cancer (Neo-CheckRay trial)

为冷肿瘤“升温”：Luminal B型乳腺癌中免疫和腺苷通路重编程的单细胞图谱（Neo-CheckRay试验）

讲者：Marcela Carausu, Institut Jules Bordet, Brussels, Belgium

GS2-05：Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

来自TBCRC-053 (P-RAD)研究HR+/HER2-队列的主要结果：一项在淋巴结阳性、HER2阴性乳腺癌中进行的无、低或高剂量术前放疗联合帕博利珠单抗和化疗的随机试验

讲者：Gaorav Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC

GS2-06：Discussant for GS2-05

讲者：Stephen Shiao

GS2-07：Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694

术前乳腺磁共振成像（MRI）分期对早期乳腺癌局部区域复发（LRR）的影响：Alliance A011104/ACRIN 6694 试验

讲者：Isabelle Bedrosian, University of Texas MD Anderson Cancer Center, Houston, TX

GS2-08：Discussant for GS2-07

讲者：Bruce Mann, Royal Melbourne Hospital, Melbourne, Australia

GS2-09：The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505)

LORETTA试验（JCOG1505）：在ER+/HER2-低风险乳腺导管原位癌（DCIS）中，仅使用他莫昔芬而不进行手术的单臂验证性试验

讲者：Hiroji Iwata, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

GS2-10：Discussant for GS2-09

讲者：Eric P. Winer, Yale Cancer Center, New Haven, CT

GS2-11：Omission of sentinel lymph node biopsy in clinically T1-2 node-negative breast cancer patients treated with breast-conserving therapy: results of the Dutch BOOG 2013-08 randomized controlled trial after a median follow-up of 5 years

在接受保乳治疗的临床T1-2期淋巴结阴性乳腺癌患者中省略前哨淋巴结活检：荷兰BOOG 2013-08随机对照试验中位随访5年后的结果

讲者：M. L. Smidt, Maastricht University Medical Center+, Maastricht, Netherlands

GS2-12：Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): final 10-year analysis of a randomised, factorial, multicentre, open-label, phase 3 study

非低风险乳腺导管原位癌的放射剂量和分割方案（BIG 3-07/TROG 07.01）：一项随机、析因、多中心、开放标签、3期研究的最终10年分析

讲者：Boon H Chua, University of New South Wales, Sydney, Australia

GS3-01：Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2

绝经激素治疗与 BRCA1 或 BRCA2 致病性变异女性的乳腺癌风险

讲者：Joanne Kotsopoulos, Women's College Hospital, Toronto, ON, Canada

GS3-02：Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) study

绝经前早期乳腺癌女性的生育力与卵巢功能保存：来自多中心前瞻性妊娠与生育力（PREFER）研究的结果

讲者：Matteo Lambertini, University of Genova – IRCCS Ospedale Policlinico San Martino, Genoa, Italy

GS3-03：Randomized controlled trial of Young, Empowered & Strong (YES), an mHealth intervention for adolescent and young adult breast cancer survivors

“Young, Empowered & Strong”（YES）移动健康（mHealth）干预用于青少年与年轻成人乳腺癌幸存者的随机对照试验

讲者：Ann H Partridge, Dana-Farber Cancer Institute, Boston, MA

GS3-04：Effects of Acupuncture vs Sham Acupuncture and Usual Care on Cancer-Related Cognitive Difficulties Among Breast Cancer Survivors: The ENHANCE Randomized Clinical Trial

ENHANCE随机临床试验：针刺疗法对比假针刺疗法与常规护理对乳腺癌幸存者癌症相关认知障碍的影响

讲者：Jun Mao, Memorial Sloan Kettering Cancer Center, New York, NY

GS3-05：Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial

在NRG/NSABP B-42试验中，评估内分泌治疗敏感性（SETER/PR）检测预测延长内分泌治疗获益的价值

讲者：Eleftherios P Mamounas, AdventHealth Cancer Institute, Orlando, FL

GS3-06：Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer

在 luminal 型乳腺癌中，CDK4/6 抑制剂治疗后视网膜母细胞瘤蛋白（Rb）作为ER靶点的转录激活因子发挥作用

讲者：April C Watt, Peter MacCallum Cancer Centre, Melbourne, Australia

GS3-07：Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

基于风险的乳腺癌筛查是安全的，更受女性青睐，并能识别出高风险人群：来自WISDOM 1.0研究的结果

讲者：Laura J Esserman, UCSF, San Francisco, CA

GS3-08：imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial

imlunestrant联合或不联合阿贝西利用于晚期乳腺癌：来自 3 期 EMBER-3 试验的更新疗效结果

讲者：Komal L Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY

GS3-09：Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor

evERA乳腺癌研究的临床和生物标志物亚组分析：一项在既往接受过CDK4/6抑制剂治疗的ER+/HER2-晚期乳腺癌患者中进行的Giredestrant联合依维莫司的III期试验

讲者：Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

GS3-10：Expanding Therapeutic Options in Hormone Receptor Positive Metastatic Breast Cancer

扩展激素受体阳性转移性乳腺癌的治疗选择

讲者：Nicholas Turner, Institute of Cancer Research, London, United Kingdom

RF1-01：Postoperative Complication Rates of Minimally Invasive Mastectomy Compared to Conventional Mastectomy: A Prospective Multicenter Cohort Study (MARRES)

微创乳房切除术与传统乳房切除术的术后并发症发生率比较：一项前瞻性多中心队列研究（MARRES）

讲者：Hyung Seok Park, Yonsei University College of Medicine, Seoul, Korea, Republic of

RF1-02：Surgical outcomesin the ALTERNATE trial (Alliance A011106) -a randomized phase 3 neoadjuvant endocrine therapy (NET) trial in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC)

ALTERNATE 试验（Alliance A011106）的手术结局:一项针对临床 Ⅱ/Ⅲ 期ER+/HER2-乳腺癌绝经后女性的新辅助内分泌治疗（NET）随机 3 期试验

讲者：Ann Marilyn Leitch, UT Southwestern Medical Center, Dallas, TX

RF1-03：Magnetic resonance imaging based internal mammary node response after neoadjuvant therapy to guide postoperative internal mammary node boost radiotherapy in breast cancer

基于磁共振成像的新辅助治疗后内乳淋巴结反应指导乳腺癌术后内乳淋巴结补量放疗

讲者：彭雨硕，北京大学肿瘤医院，中国北京

RF1-04：Early Adverse Symptoms Predict Response to Treatment Among Patients in the I-SPY Trial

早期不良症状预测 I-SPY 试验患者的治疗反应

讲者：Amrita Basu, University of California San Francisco, San Francisco, CA

RF1-05：Utilization of ePROs and smart pill bottles to improve adherence to adjuvant endocrine therapy in early-stage breast cancer

利用电子化患者报告结局（ePROs）与智能药瓶提高早期乳腺癌辅助内分泌治疗的依从性

讲者：Steven A Manobianco, Sidney Kimmel Comprehensive Cancer Center – Jefferson Health, Philadelphia, PA

RF1-06：Discordance in End-of-Life Decision-Making: A Quantitative Study on the Values and Preferences of Japanese Cancer Patients and Their Family Members

终末期决策的不一致性：日本癌症患者与其家属价值观及偏好的定量研究

讲者：Akihiko Ozaki, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan

RF1-07：Cruciferous vegetable intake, dietary glucosinolate and risk of breast cancer in 2 large prospective studies

两项大型前瞻性研究中十字花科蔬菜摄入、膳食硫代葡萄糖苷与乳腺癌风险的关联

讲者：Andrea Romanos-Nanclares, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

RF2-01：Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials

早期三阴性乳腺癌（TNBC）新辅助化疗（NACT）后残留肿瘤中的预后标志物——来自九项GBG/AGO-B新辅助试验的汇总分析

讲者：Johannes Holtschmidt, GBG c/o GBG Forschungs GmbH, Neu Isenburg, Germany

RF2-02：Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer

BrighTNess、CALGB 40603（Alliance）与 GeparSixto 临床试验的汇总分析确定新辅助卡铂对早期三阴性乳腺癌pCR与生存的影响

讲者：Brooke M Felsheim, University of North Carolina at Chapel Hill, Chapel Hill, NC

RF2-03：Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial

辅助表柔比星联合环磷酰胺序贯紫杉烷联合或不联合卡铂用于早期三阴性乳腺癌（RJBC 1501）：一项随机对照 3 期试验

讲者：陈小松, 上海交通大学医学院附属瑞金医院, 中国上海

RF2-04：Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial

辅助卡铂强化化疗对比标准化疗对高危早期TNBC女性生存的影响：一项随机 3 期试验（CITRINE）

讲者：邵志敏, 复旦大学附属肿瘤医院, 中国上海

RF2-06：mpact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Substudy of the NSABP B-59/GBG-96-GeparDouze Trial

NSABP B-59/GBG-96-GeparDouze试验的一项前瞻性子研究：免疫检查点抑制剂（CPI）对接受新辅助化疗（NACT）的年轻早期TNBC女性生育力的影响

讲者：Mattea Reinisch, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany

RF2-07：Nodal disease burden in patients with clinically node-positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting: pre-planned TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

新辅助治疗与初始手术场景下接受个体化腋窝手术联合或不联合腋窝清扫的临床淋巴结阳性乳腺癌患者的淋巴结病变负荷：TAXIS 研究（OPBC-03、SAKK 23/16、IBCSG 57-18、ABCSG-53、GBG 101）预设分析

讲者：Walter P. Weber, University of Basel, Basel, Switzerland & Breast Clinic, University Hospital Basel, Basel, Switzerland

RF3-01：Clinical outcomes of invasive lobular carcinoma (ILC) versus non-lobular breast cancer (NLC) assessed by expert pathologists, an artificial intelligence (AI) CDH1 classifier, and AI-derived tumor microenvironment (TME) biomarkers in TAILORx

TAILORx 试验中经病理学家、人工智能（AI）CDH1 分类器及 AI 衍生肿瘤微环境（TME）生物标志物评估的浸润性小叶癌（ILC）与非小叶型乳腺癌（NLC）的临床结局

讲者：Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia

RF3-02：Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

基于基因表达的早期TNBC分型用于预测 NSABP B-59/GBG-96-GeparDouze 试验中新辅助免疫化疗的反应

讲者：Carsten Denkert, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany

RF3-04：Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial

在PALLAS试验中，利用肿瘤信息指导的ctDNA分析评估分子残留病灶，以预测哌柏西利的预后和获益

讲者：Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

RF3-05：Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial

来自c-TRAK-TN试验的早期TNBC患者的无组织ctDNA检测

讲者：Niamh Cunningham, Royal Marsden Hospital, London, United Kingdom

RF3-06：Tumor infiltrating lymphocytes in post-NACT residual tumors in ECOG-ACRIN EA1131 – impact of intrinsic subtypes.

ECOG-ACRIN EA1131 试验中新辅助化疗后残留肿瘤的肿瘤浸润淋巴细胞：内在亚型的影响

讲者：Sunil S Badve, Emory School of Medicine, Atlanta, GA

RF3-07：A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer

在 NSABP B-42 试验中训练并在 TAILORx 试验中验证的多模态多任务深度学习模型用于预测 HR+ 早期乳腺癌的晚期远处复发风险

讲者：Eleftherios Mamounas, National Surgical Adjuvant Breast and Bowel Project and AdventHealth Cancer Institute, Orlando, FL

RF4-01：Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)

3 期 PATINA 试验（AFT-38）的中枢神经系统结局

讲者：Otto Metzger, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

RF4-02：Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer

随机 3 期 DETECT V 试验的疗效分析：HER2阳性、激素受体阳性转移性乳腺癌中省略化疗的治疗降阶及联合瑞波西利的效果

讲者：Wolfgang Janni, University Hospital Ulm, Ulm, Germany

RF4-03：Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05

DESTINY-Breast05研究的中期分析：T-DXd对比T-DM1用于新辅助治疗后仍有残留浸润性病灶的高危HER2+原发性乳腺癌患者

讲者：Sibylle Loibl, GBG Neu-Isenburg and Goethe University, Neu-Isenburg, Germany

RF4-04：Mechanisms of resistance to capivasertib in combination with CDK4/6 inhibitor (CDK4/6i) plus fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced breast cancer (ABC): exploratory analysis from the Phase 1b CAPItello-292 study

CAPItello-292 1b期研究的探索性分析：HR+/HER2-晚期乳腺癌患者中，对卡匹色替联合CDK4/6抑制剂及氟维司群的耐药机制

讲者：Dhivya Raja Sudhan, AstraZeneca, Gaithersburg, MD

RF4-05：PIK3R1 (p85α) alterations define a targetable subset of breast cancer with broad sensitivity to PI3K and AKT inhibitors

PIK3R1 (p85α) 改变定义了一个对PI3K和AKT抑制剂具有广泛敏感性的可靶向乳腺癌亚群

讲者：Shalinda Fernando, NYU Langone, New York, NY

RF4-06：FDG-PET/CT to assess therapeutic response in patients with bone-dominant metastatic breast cancer, FEATURE: ECOG-ACRIN EA1183

FEATURE研究（ECOG-ACRIN EA1183）：使用FDG-PET/CT评估骨显性转移性乳腺癌患者的治疗反应

讲者：Jennifer M Specht, University of Washington/Fred Hutch Cancer Center, Seattle, WA

RF4-07：Genomic characteristics of de novo HER2-positive metastatic breast cancer

新发HER2阳性转移性乳腺癌的基因组特征

讲者：Shu Yazaki, Memorial Sloan Kettering Cancer Center, New York, NY

RF5-01：Cancer-specific risks associated with germline PALB2 pathogenic variants from a large clinical genetic testing cohort

来自大型临床基因检测队列的与种系PALB2致病性变异相关的癌症特异性风险

讲者：Yen Y. Tan, Medical University of Vienna, Vienna, Austria

RF5-02：Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts

TBCRC 056研究：一项在BRCA或PALB2突变的乳腺癌患者中进行的新辅助尼拉帕利联合多塔利单抗的2期研究：来自TNBC队列的结果

讲者：Erica L Mayer, Dana-Farber Cancer Institute, Boston, MA

RF5-03：Olympian: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with brca mutations and early-stage her2-negative breast cancer

Olympian研究：一项评估奥拉帕利单药及奥拉帕利联合度伐利尤单抗新辅助治疗 BRCA 突变、早期 HER2 阴性乳腺癌患者疗效与安全性的多中心、开放标签 2 期研究

讲者：Nadine Tung, Beth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center, Boston, MA

RF5-04：Germline pathogenic variants in the personalized screening arm of the WISDOM Study: Findings from 23,098 women with no personal history of breast cancer

WISDOM 研究个体化筛查组中的种系致病性变异：来自 23098 例无乳腺癌个人史女性的结果

讲者：Kirkpatrick B. Fergus, University of California San Francisco, San Francisco, CA

RF5-05：Predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: Primary analysis of the RADIOLA phase II trial

RADIOLA II期试验的初步分析：通过RAD51检测根据同源重组状态预测携带BRCA1/2、PALB2、RAD51C/D突变的转移性HER2阴性乳腺癌患者对奥拉帕利的敏感性

讲者：Isabel Pimentel, Vall d’Hebron University Hospital / Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

RF5-06：Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial

新型HER2 ADC药物ARX788治疗后的pCR：来自I-SPY2.2试验的结果

讲者：Paula R Pohlmann, University of Texas MD Anderson Cancer Center, Houston, TX

RF6-01：Associations Between Cardiac Radiation Dose Volume Metrics and Cardiac Specific Health Related Quality of Life for Patients with Breast Cancer Randomized to Proton versus Photon Radiation on the RadComp Trial

RadComp试验中，随机接受质子与光子放疗的乳腺癌患者的心脏放疗剂量体积指标与心脏特异性健康相关生活质量之间的关联

讲者：Jean L Wright, University of North Carolina, Chapel Hill, NC

RF6-02：Patient-reported outcomes (PROs) in DESTINY-Breast11: neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

DESTINY-Breast11研究中的PROs：在高危HER2+早期乳腺癌中，新辅助T-DXd单药治疗或序贯紫杉醇+曲妥珠单抗+帕妥珠单抗（THP）对比剂量密集多柔比星+蒽环类药物序贯THP（ddAC-THP）的疗效

讲者：Shanu Modi, Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY

RF6-03：DESTINY-Breast11 (DB-11) safety: neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

DESTINY-Breast11 (DB-11) 的安全性：在高危HER2+早期乳腺癌中，新辅助T-DXd单药治疗或序贯THP对比剂量密集多柔比星+蒽环类药物序贯THP（ddAC-THP）的安全性

讲者：Giuseppe Curigliano, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS & Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy

RF6-04：Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study

DESTINY-Breast09研究的PROs：T-DXd+帕妥珠单抗（P）对比THP用于HER2阳性晚期/转移性乳腺癌患者的一线治疗

讲者：Mothaffar Rimawi, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

RF7-03：Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

SERENA-6试验的更新结果和ESR1突变ctDNA动态的探索性分析：一项在HR+/HER2-晚期乳腺癌患者一线内分泌治疗期间出现ESR1突变且疾病进展前，使用Camizestrant+CDK4/6抑制剂的3期试验

讲者：François-Clément Bidard, Institut Curie, Paris, France

RF7-04：Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

VIKTORIA-1随机3期试验的更新结果：多靶点PI3K/AKT/mTOR（PAM）抑制剂Gedatolisib联合氟维司群（联合或不联合哌柏西利）用于HR+/HER2-/PIK3CA野生型（WT）晚期乳腺癌患者的二线治疗

讲者：Barbara Pistilli, Gustave Roussy, Villejuif, France

RF7-05：Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial

卡匹色替联合氟维司群治疗HR+晚期乳腺癌：Ⅲ 期 CAPItello-291 试验的探索性ctDNA分析

讲者：Nicholas C Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

RF7-06：Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden

Ambre研究的主要结果：一项比较单药化疗与阿贝西利+内分泌治疗用于高内脏肿瘤负荷 HR+/HER2-晚期乳腺癌的随机 3 期试验

讲者：Véronique Dieras, Centre Eugène Marquis, Rennes, France

RF7-07：Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival

PALLAS试验（ABCSG-42/AFT-05/PrE0109/BIG-14-13）：哌柏西利辅助治疗ER+乳腺癌的复发后治疗和总生存期

讲者：Angela DeMichele, University of Pennsylvania, Philadelphia, PA

注：本文信息整理自SABCS会议官网，内容截至发稿之日。会议议程或有更新，最终信息请以大会官方发布为准。